Clinical Trials › NCT05344469
Recruiting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Sponsored by Novartis Pharmaceuticals
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 800
Target enrollment
May 2022
Start date
May 2029
Expected completion
Interventions / Treatments
ofatumumabglatiramer acetateinterferon β1teriflunomidedimethyl fumarate (DMF)diroximel fumarate (DRF)
Conditions studied
Relapsing Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.